Affiliation:
1. 1Department of Technology, Faculty of Health and Technology, University College Copenhagen, Copenhagen, Denmark.
2. 2Copenhagen City Heart Study, Copenhagen University Hospital, Copenhagen, Denmark.
3. 3Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
Abstract
Background:
Screening reduces lung cancer mortality, but specificities of eligibility criteria are low. We tested if leukocyte AHRR(cg05575921) methylation improves specificity of lung cancer screening eligibility criteria.
Methods:
A total of 9,206 and 5,370 individuals of the 1991 to 1994 and 2001 to 2003 examinations of the Copenhagen City Heart Study, Denmark, were followed for lung cancer within 5 years after examination and mortality. Screening eligibility criteria (DANTE, DLCST, ITALUNG, LUSI, NELSON, NLST, and PLCOM2012) were evaluated, and AHRR (cg05575921) methylation extent at different methylation cut points was added. The model with the lowest number of eligible individuals per 5-year lung cancer was validated within the 2001 to 2003 examination.
Results:
Eligibility criteria identified risk-groups ranging from 3,182 (DANTE) to 1,641 (ITALUNG) individuals. The positive predictive value was highest for PLCOM2012 (3.2%), while DANTE showed the highest negative predictive value (99.7%). Adding AHRR (cg05575921) methylation led to higher specificities for all criteria. Number of eligible individuals per 5-year lung cancer varied from 38 (NELSON) to 27 (NLST) with AHRR (cg05575921) methylation <55%. This last model led to a 21.9% lower screening burden and increased (P < 0.05) specificity of 84.0%. Findings were reproduced among the 5,334 individuals of the 2001 to 2003 examination.
Conclusions:
Adding AHRR (cg05575921) methylation on top of current eligibility criteria for lung cancer screening improves specificity by excluding those individuals with the lowest risk.
Impact:
The results point toward a potential clinical use of AHRR (cg05575921) methylation, which is a cost-effective measurement compared with lung CT scanning, to provide additional predictive risk information to identify eligible smokers for lung cancer screening.
See related commentary by Hung, p. 698
Funder
Harboefonden
Dagmar Marshalls Fond
Overlæge Johan Boserup og Lise Boserups Legat
Publisher
American Association for Cancer Research (AACR)
Reference43 articles.
1. Cancer Fact sheet;World Health Organization,2018
2. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study 2004–2007;Walters;Thorax,2013
3. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population based study;De Angelis;Lancet Oncol,2014
4. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
5. Reduced lung-cancer mortality with volume CT screening in a randomized trial;de Koning;N Engl J Med,2020
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献